In addition, EGCG treatment has been reported to affect angiogenesis in the TME, which could also partially contribute to the tumor-suppressing effect of EGCG [60,61] and might explain differential effects of EGCG and the anti-PD-1 antibody treatment, reflected by Ki-67 staining shown in Figure 3E. This evidence concerns the gene MKI67 and neoplasm.